|
|
Article: ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results.
- Article from:
- Blood Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced financial results for the three-month period ended September 30, 2009 - the first quarter of the Company's 2010 fiscal year (1QFY10) (see also ImmunoGen, Inc.).
"In the next two months, we expect data from five clinical studies to be presented at major medical meetings - the results from the T-DM1 Phase II study that could support a registration filing in 2010 if the findings are compelling, updated clinical data with our IMGN901 compound in the treatment of both CD56-expressing ...